Growth Outcomes of Preterm Infants Exposed to Different Oxygen Saturation Target Ranges from Birth
- PMID: 27344218
- PMCID: PMC5327617
- DOI: 10.1016/j.jpeds.2016.05.070
Growth Outcomes of Preterm Infants Exposed to Different Oxygen Saturation Target Ranges from Birth
Abstract
Objective: To test whether infants randomized to a lower oxygen saturation (peripheral capillary oxygen saturation [SpO2]) target range while on supplemental oxygen from birth will have better growth velocity from birth to 36 weeks postmenstrual age (PMA) and less growth failure at 36 weeks PMA and 18-22 months corrected age.
Study design: We evaluated a subgroup of 810 preterm infants from the Surfactant, Positive Pressure, and Oxygenation Randomized Trial, randomized at birth to lower (85%-89%, n = 402, PMA 26 ± 1 weeks, birth weight 839 ± 186 g) or higher (91%-95%, n = 408, PMA 26 ± 1 weeks, birth weight 840 ± 191 g) SpO2 target ranges. Anthropometric measures were obtained at birth, postnatal days 7, 14, 21, and 28; then at 32 and 36 weeks PMA; and 18-22 months corrected age. Growth velocities were estimated with the exponential method and analyzed with linear mixed models. Poor growth outcome, defined as weight <10th percentile at 36 weeks PMA and 18-22 months corrected age, was compared across the 2 treatment groups by the use of robust Poisson regression.
Results: Growth outcomes including growth at 36 weeks PMA and 18-22 months corrected age, as well as growth velocity were similar in the lower and higher SpO2 target groups.
Conclusion: Targeting different oxygen saturation ranges between 85% and 95% from birth did not impact growth velocity or reduce growth failure in preterm infants.
Keywords: ELBW growth; oxygen saturation target.
Copyright © 2016 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Oxygen Saturation Targeting for Infants with Bronchopulmonary Dysplasia: A Pilot Randomized Trial.Ann Am Thorac Soc. 2025 Apr;22(4):560-569. doi: 10.1513/AnnalsATS.202404-443OC. Ann Am Thorac Soc. 2025. PMID: 40167293 Clinical Trial.
-
Reference Ranges for Arterial Oxygen Saturation, Heart Rate, and Cerebral Oxygen Saturation during Immediate Postnatal Transition in Neonates Born Extremely or Very Preterm.J Pediatr. 2024 Oct;273:114132. doi: 10.1016/j.jpeds.2024.114132. Epub 2024 May 31. J Pediatr. 2024. PMID: 38823628
-
Postnatal length and weight growth velocities according to Fenton reference and their associated perinatal factors in healthy late preterm infants during birth to term-corrected age: an observational study.Ital J Pediatr. 2019 Jan 3;45(1):1. doi: 10.1186/s13052-018-0596-4. Ital J Pediatr. 2019. PMID: 30606228 Free PMC article.
-
Meta-analysis of Oxygenation Saturation Targeting Trials: Do Infant Subgroups Matter?Clin Perinatol. 2019 Sep;46(3):579-591. doi: 10.1016/j.clp.2019.05.003. Epub 2019 Jun 10. Clin Perinatol. 2019. PMID: 31345548 Review.
-
SpO2 and retinopathy of prematurity: state of the art.J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 4:108-10. doi: 10.3109/14767058.2012.714982. J Matern Fetal Neonatal Med. 2012. PMID: 22958036 Review.
Cited by
-
Thresholds for surfactant use in preterm neonates: a network meta-analysis.Arch Dis Child Fetal Neonatal Ed. 2023 Jul;108(4):333-341. doi: 10.1136/archdischild-2022-324184. Epub 2022 Dec 9. Arch Dis Child Fetal Neonatal Ed. 2023. PMID: 36600484 Free PMC article.
-
Growth Rates of Infants Randomized to Continuous Positive Airway Pressure or Intubation After Extremely Preterm Birth.J Pediatr. 2021 Oct;237:148-153.e3. doi: 10.1016/j.jpeds.2021.06.026. Epub 2021 Jun 19. J Pediatr. 2021. PMID: 34157349 Free PMC article. Clinical Trial.
-
Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity.J AAPOS. 2018 Feb;22(1):61-65.e1. doi: 10.1016/j.jaapos.2017.10.006. Epub 2017 Dec 6. J AAPOS. 2018. PMID: 29223789 Free PMC article. Clinical Trial.
-
Severity of Bronchopulmonary Dysplasia in Infants Born Extremely Preterm and Randomized to Early Human Milk Fortification with a Donor Milk-Derived Fortifier for 2 Weeks.J Pediatr. 2025 Jul 24;287:114750. doi: 10.1016/j.jpeds.2025.114750. Online ahead of print. J Pediatr. 2025. PMID: 40714049
References
-
- Dusick AM, Poindexter BB, Ehrenkranz RA, Lemons JA. Growth failure in the preterm infant: can we catch up? Semin Perinatol. 2003;27:302–310. - PubMed
-
- Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics. 2001;107:E1. - PubMed
-
- Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstetrics and gynecology. 1996;87:163–168. - PubMed
-
- Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics. 2006;117:1253–1261. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 HD021385/HD/NICHD NIH HHS/United States
- U10 HD021364/HD/NICHD NIH HHS/United States
- UG1 HD053089/HD/NICHD NIH HHS/United States
- UG1 HD034216/HD/NICHD NIH HHS/United States
- U10 HD027871/HD/NICHD NIH HHS/United States
- U10 HD027851/HD/NICHD NIH HHS/United States
- UG1 HD027880/HD/NICHD NIH HHS/United States
- UG1 HD053109/HD/NICHD NIH HHS/United States
- UG1 HD027851/HD/NICHD NIH HHS/United States
- UG1 HD068278/HD/NICHD NIH HHS/United States
- U10 HD053089/HD/NICHD NIH HHS/United States
- U10 HD027856/HD/NICHD NIH HHS/United States
- U10 HD021373/HD/NICHD NIH HHS/United States
- U10 HD053119/HD/NICHD NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- U10 HD027880/HD/NICHD NIH HHS/United States
- UG1 HD027853/HD/NICHD NIH HHS/United States
- U10 HD053109/HD/NICHD NIH HHS/United States
- U10 HD040689/HD/NICHD NIH HHS/United States
- U10 HD040492/HD/NICHD NIH HHS/United States
- U10 HD027853/HD/NICHD NIH HHS/United States
- U10 HD021397/HD/NICHD NIH HHS/United States
- UG1 HD040492/HD/NICHD NIH HHS/United States
- UG1 HD021364/HD/NICHD NIH HHS/United States
- U10 HD034216/HD/NICHD NIH HHS/United States
- U10 HD036790/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases